Bruce A. Schwartz

2.2k total citations · 1 hit paper
33 papers, 1.7k citations indexed

About

Bruce A. Schwartz is a scholar working on Hematology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Bruce A. Schwartz has authored 33 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 9 papers in Pulmonary and Respiratory Medicine and 8 papers in Surgery. Recurrent topics in Bruce A. Schwartz's work include Platelet Disorders and Treatments (13 papers), Hemophilia Treatment and Research (9 papers) and Heparin-Induced Thrombocytopenia and Thrombosis (7 papers). Bruce A. Schwartz is often cited by papers focused on Platelet Disorders and Treatments (13 papers), Hemophilia Treatment and Research (9 papers) and Heparin-Induced Thrombocytopenia and Thrombosis (7 papers). Bruce A. Schwartz collaborates with scholars based in United States, Italy and United Kingdom. Bruce A. Schwartz's co-authors include John R. Hoidal, Walter Rubin, Craig M. Kessler, Alfred F. Michael, James W. Leatherman, Mary Cushman, Rolf Paulson, Paul M. Ridker, Kenneth A. Bauer and Stephan Moll and has published in prestigious journals such as Science, New England Journal of Medicine and Blood.

In The Last Decade

Bruce A. Schwartz

31 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism

2003 551 citations Paul M. Ridker, Samuel Z. Goldhaber et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Bruce A. Schwartz

Since Specialization

Citations

This map shows the geographic impact of Bruce A. Schwartz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruce A. Schwartz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruce A. Schwartz more than expected).

Fields of papers citing papers by Bruce A. Schwartz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bruce A. Schwartz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruce A. Schwartz. The network helps show where Bruce A. Schwartz may publish in the future.

Co-authorship network of co-authors of Bruce A. Schwartz

This figure shows the co-authorship network connecting the top 25 collaborators of Bruce A. Schwartz. A scholar is included among the top collaborators of Bruce A. Schwartz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bruce A. Schwartz. Bruce A. Schwartz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Protocol for a multicentre, randomised, parallel-control, superiority trial comparing administration of clotting factor concentrates with a standard massive haemorrhage protocol in severely bleeding trauma patients: the FiiRST 2 trial (a 2020 EAST multicentre trial) 2021 ·BMJ Open ·Luís Teodoro da Luz, Jeannie Callum, Andrew Beckett, Hans-Peter Hucke, Jo Carroll, Deep Grewal, Bruce A. Schwartz, Henry T. Peng, Paul T. Engels, Neil Parry, Andrew Petrosoniak, Homer Tien, Avery B. Nathens, Damon C. Scales, Keyvan Karkouti	9
2	Fiirst-2: Prospective, Randomized Study Comparing Administration of Clotting Factor Concentrates with Standard Massive Hemorrhage Protocol in Severely Bleeding Trauma Patients 2020 ·Blood ·Luís Teodoro da Luz, Jeannie Callum, Andrew Beckett, Henry T. Peng, Paul T. Engels, Neil Parry, Homer Tien, Avery B. Nathens, Bruce A. Schwartz, Keyvan Karkouti	1
3	Fibrinogen concentrate for treatment of bleeding and surgical prophylaxis in congenital fibrinogen deficiency patients 2019 ·Journal of Thrombosis and Haemostasis ·Toshko Lissitchkov, Bella Madan, Claudia Djambas Khayat, (unknown), Cecil Ross, Mehran Karimi, Kaan Kavaklı, (unknown), Abdulkareem Al-Momen, (unknown), (unknown), Auro Viswabandya, Hamid Hoorfar, Bruce A. Schwartz, Cristina Solomon, Sigurd Knaub, Flora Peyvandi	25
4	Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency 2017 ·Journal of Thrombosis and Haemostasis ·Cecil Ross, Savita Rangarajan, Mehran Karimi, Gholamreza Toogeh, Shashikant Apte, Toshko Lissitchkov, Sourya Acharya, Marilyn J. Manco‐Johnson, Alok Srivastava, B. Brand, Bruce A. Schwartz, Sigurd Knaub, Flora Peyvandi	32
5	Pharmacokinetic (PK) Comparison of Two Fibrinogen Concentrates for the Treatment of Congenital Fibrinogen Deficiency 2014 ·Blood ·Bruce A. Schwartz, Savita Rangarajan, Flora Peyvandi, Mehran Karimi, Sigurd Knaub	1
6	Use of objective efficacy criteria for evaluation of von willebrand factor/factor VIII concentrates 2012 ·Blood Coagulation & Fibrinolysis ·Craig M. Kessler, Jerzy Windyga, Bruce A. Schwartz, Sigurd Knaub	4
7	The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease 2011 ·Thrombosis and Haemostasis ·Craig M. Kessler, (unknown), Bruce A. Schwartz, Joan Cox Gill, Jerry S. Powell, (unknown)	25
8	ITI with a VWF-Stabilised FVIII Concentrate in Haemophilia A Patients with Inhibitors and a Poor Prognosis for ITI Success: Progress Report on octanate® in the Observational ObsITI Study, 2011 ·Blood ·C. Escuriola‐Ettingshausen, (unknown), (unknown), (unknown), W. Kreuz, Bruce A. Schwartz	3
9	Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate‐P^®) 2004 ·Haemophilia ·Arthur R. Thompson, Joan Cox Gill, Bruce M. Ewenstein, Guenther Mueller‐Velten, Bruce A. Schwartz, (unknown)	76
10	Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate‐P^®): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy 2003 ·Haemophilia ·Joan Cox Gill, Bruce M. Ewenstein, Arthur R. Thompson, Guenther Mueller‐Velten, Bruce A. Schwartz, (unknown)	55
11	Continuous intravenous infusion of a plasma‐derived factor IX concentrate (Mononine^®) in haemophilia B 2003 ·Haemophilia ·W. Keith Hoots, Cindy Leissinger, (unknown), Bruce A. Schwartz, G C White, (unknown), (unknown), Claude Négrier, F. Schindel, Sam Schulman	25
12	Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism breakdown → 2003 ·New England Journal of Medicine ·Paul M. Ridker, Samuel Z. Goldhaber, (unknown), Yves Rosenberg, Charles S. Eby, Steven R. Deitcher, Mary Cushman, Stephan Moll, Craig M. Kessler, C. Gregory Elliott, Rolf Paulson, Turnly Wong, Kenneth A. Bauer, Bruce A. Schwartz, Joseph P. Miletich, Henri Bounameaux, Robert J. Glynn	551
13	Pharmacokinetic analysis of plasma‐derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B 2002 ·Transfusion ·Bruce M. Ewenstein, J. Heinrich Joist, Amy D. Shapiro, Thomas Hofstra, Cindy Leissinger, Stephanie Seremetis, Martin I. Broder, Guenther Mueller‐Velten, Bruce A. Schwartz, (unknown)	85
14	Evaluation of high concentration intranasal and intravenous desmopressin in pediatric patients with mild hemophilia A or mild-to-moderate type 1 von Willebrand disease 2002 ·The Journal of Pediatrics ·Joan Cox Gill, (unknown), Bruce A. Schwartz	15
15	Cigarette smoking causes accumulation of polymorphonuclear leukocytes in alveolar septum. 1985 ·PubMed ·(unknown), Bruce A. Schwartz, John R. Hoidal, Dennis E. Niewoehner	63
16	Protection against pulmonary oxygen toxicity in rats by the intratracheal administration of liposome-encapsulated superoxide dismutase or catalase. 1985 ·PubMed ·Rama Padmanabhan, (unknown), I. E. Liener, Bruce A. Schwartz, John R. Hoidal	118
17	Protection Against Lethal Hyperoxia by Tracheal Insufflation of Erythrocytes: Role of Red Cell Glutathione 1985 ·Science ·B. Sweder van Asbeck, John R. Hoidal, Gregory M. Vercellotti, Bruce A. Schwartz, Charles F. Moldow, Harry S. Jacob	142
18	An Electron Microscopic Radioautographic Identification of the APUD Endocrine Cells in the Rat Gastric Pyloric Glands 1981 ·Gastroenterology ·Walter Rubin, Bruce A. Schwartz	10
19	An electron microscopic radioautographic identification of the "enterochromaffin-like" APUD cells in murine oxyntic glands. Demonstration of a metabolic difference between rat and mouse gastric A-like cells. 1979 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·Walter Rubin, Bruce A. Schwartz	21
20	An Electron Microscopic Radioautographic Identification of the “Enterochromaffin-Like” APUD Cells in Murine Oxyntic Glands 1979 ·Gastroenterology ·Walter Rubin, Bruce A. Schwartz	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact